• Potential window for treating ALS identi

    From ScienceDaily@1:317/3 to All on Tue Mar 29 22:30:40 2022
    Potential window for treating ALS identified

    Date:
    March 29, 2022
    Source:
    Johns Hopkins Medicine
    Summary:
    Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
    that affects as many as 30,000 people in the United States, with
    5,000 new cases diagnosed each year. It weakens muscles over time,
    impacting physical function and ultimately leading to death. There
    is no single cause for the disease and no known cure. However,
    researchers have found a possible window of opportunity during
    ALS treatment to target astrocyte abnormalities.



    FULL STORY ========================================================================== Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
    that affects as many as 30,000 people in the United States, with 5,000
    new cases diagnosed each year. It weakens muscles over time, impacting
    physical function and ultimately leading to death. There is no single
    cause for the disease and no known cure. However, Johns Hopkins Medicine researchers have found a possible window of opportunity during ALS
    treatment to target astrocyte abnormalities -- a subtype of cells in
    the central nervous system that provide a structure to metabolically
    support neurons and fine-tune neuron network signaling.


    ==========================================================================
    The research team believes that astrocytes are actively involved in
    the death of motor neurons, which are cells in the brain and spinal
    cord that allow people to move, speak, swallow and breathe by sending
    commands from the brain to the muscles that carry out these functions.

    "We think this is particularly important because the astrocyte dysfunction
    is active after symptom onset in patients with ALS," says Nicholas
    Maragakis, M.D., professor of neurology at the Johns Hopkins University
    School of Medicine and medical director of the Johns Hopkins ALS clinical trials unit. "This finding may enable us to target abnormalities in
    astrocytes for ALS treatment." In their study, published March 21 in the Proceedings of the National Academy of Sciences, researchers analyzed
    brain and spinal cord tissues from patients with ALS and observed that
    a particular astrocyte protein, connexin 43, acts as an open pore that
    sends toxic factors to the motor neurons from the astrocytes.

    The pore was particularly active in patients with ALS who have a family
    history of the disease and those who contracted the disease in a sporadic fashion.

    The research team was also able to develop stem cell lines from patients
    with ALS and develop them into astrocytes. They found that these
    astrocytes induced motor neuron death through hemichannels (proteins
    that provide pathways for the movement of molecules among cells).

    "This is a new pathway that we have shown to be present in ALS tissues,
    animal models and patient-derived stem cells," Maragakis says. "It's also exciting that this particular hemichannel protein seems to be elevated
    in spinal fluid from patients with ALS and could serve as an important biomarker. This is a true precision medicine approach toward the disease." Maragakis says pharmaceuticals are being developed that could block
    this hemichannel. During the study, his team showed that tonabersat,
    a drug originally developed for treatment of migraine and epilepsy,
    could block astrocyte-induced motor neuron death in human ALS stem cell
    lines and animal models.

    This study, Maragakis says, offers increasing evidence that astrocytes
    play a role in the spread of ALS. Next, the team will try to establish
    why this hemichannel is so active in ALS astrocytes, giving them a better understanding of how the disease progresses. Maragakis says it's equally important because it furthers his team's work to identify new drugs that
    can block this particular hemichannel, serving as future therapeutics
    for ALS.

    The study was funded by the ALS Association, the Maryland Stem Cell
    Research Fund, the Robert Packard Center for ALS Research at Johns
    Hopkins, the U.S.

    Department of Defense and the National Institutes of Health.


    ========================================================================== Story Source: Materials provided by Johns_Hopkins_Medicine. Note:
    Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Akshata A. Almad, Arens Taga, Jessica Joseph, Sarah K. Gross, Connor
    Welsh, Aneesh Patankar, Jean-Philippe Richard, Khalil Rust,
    Aayush Pokharel, Caroline Plott, Mauricio Lillo, Raha Dastgheyb,
    Kevin Eggan, Norman Haughey, Jorge E. Contreras, Nicholas
    J. Maragakis. Cx43 hemichannels contribute to astrocyte-mediated
    toxicity in sporadic and familial ALS. Proceedings of the National
    Academy of Sciences, 2022; 119 (13) DOI: 10.1073/pnas.2107391119 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2022/03/220329090727.htm

    --- up 4 weeks, 1 day, 10 hours, 50 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)